Clinical symptoms and cognitive impairment associated with male schizophrenia relate to plasma manganese superoxide dismutase activity: A case-control study

Journal of Psychiatric Research

Volumn 47, Issue 8, 2013, Pages 1049-1053

  Zhang, Xiang Yang ^a,b   Chen, Da Chun ^b   Xiu, Mei Hong ^b   Tan, Yun Long ^b   Yang, Fu De ^b   Zhang, Laurence Y ^c   Zhang, Laura Y ^c   Haile, Colin N ^b   Kosten, Thomas R ^a,b  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b PEKING UNIVERSITY   (China)

^c Bellaire High School   (United States)

Author keywords

Cognition; MnSOD; Oxidative stress; Psychopathology; Schizophrenia

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; MANGANESE SUPEROXIDE DISMUTASE; PERPHENAZINE; RISPERIDONE; SULPIRIDE;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL PATIENT; OXIDATIVE STRESS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SYMPTOM;

EID: 84878654392     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2013.03.014     Document Type: Article

References (43)

1. Allott K., Liu P., Proffitt T.M., Killackey E. Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique. Schizophrenia Research 2011, 125:221-235.
2. Ames B.N. Low micronutrient intake may accelerate the degenerative diseases of aging through allocation of scarce micronutrients by triage. Proceedings of theNational Academy of Sciences of the United States of America 2006, 103:17589-17594.
3. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. American Journal of Psychiatry 2000, 157:549-559.
4. Clausen A., Doctrow S., Baudry M. Prevention of cognitive deficits and brain oxidative stress with superoxide dismutase/catalase mimetics in aged mice. Neurobiology of Aging 2010, 31(3):425-433.
5. Condray R., Yao J.K. Cognition, dopamine and bioactive lipids in schizophrenia. Frontiers in Bioscience (Scholar Edition) 2011, 3:298-330.
6. Corbetta M., Patel G., Shulman G.L. The reorienting system of the human brain: from environment to theory of mind. Neuron 2008, 58:306-324.
7. Davies K.J. Oxidative stress, antioxidant defenses, and damage removal, repair, and replacement systems. IUBMB Life 2000, 50:279-289.
8. Dickerson F., Boronow J.J., Stallings C., Origoni A.E., Cole S.K., Yolken R.H. Cognitive functioning in schizophrenia and bipolar disorder: comparison of performance on the repeatable battery for the assessment of neuropsychological status. Psychiatry Research 2004, 129:45-53.
9. Dickerson F., Stallings C., Vaughan C., Origoni A., Khushalani S., Dickinson D., Medoff D. Cognitive functioning in recent onset psychosis. Journal of Nervous and Mental Disease 2011, 199(6):367-371.
10. Fukui K., Onodera K., Shinkai T., Suzuki S., Urano S. Impairment of learning and memory in rats caused by oxidative stress and aging, and changes in antioxidative defense systems. Annals of the New York Academy of Sciences 2001, 928:168-175.
11. Granholm E., McQuaid J.R., Link P.C., Fish S., Patterson T., Jeste D.V. Neuropsychological predictors of functional outcome in cognitive behavioral social skills training for older people with schizophrenia. Schizophrenia Research 2008, 100:133-143.
12. Green M.F., Kern R.S., Braff D.L., Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the "right stuff". Schizophrenia Bulletin 2000, 26:119-136.
13. Han M., Huang X.F., Chen da C., Xiu M.H., Hui L., Liu H., et al. Gender differences in cognitive function of patients with chronic schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2012, 39(2):358-363.
14. Halari R., Mehrotra R., Sharma T., Ng V., Kumari V. Cognitive impairment but preservation of sexual dimorphism in cognitive abilities in chronic schizophrenia. Psychiatry Research 2006, 141:129-139.
15. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Journal of Clinical Psychiatry 2004, 65(3):361-372.
16. Harvey P.D. Pharmacological cognitive enhancement in schizophrenia. Neuropsychology Review 2009, 19:324-335.
17. Hu D., Serrano F., Oury T.D., Klann E. Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. Journal of Neuroscience 2006, 26:3933-3941.
18. Hughes C., Kumari V., Soni W., Das M., Binneman B., Drozd S., et al. Longitudinal study of symptoms and cognitive function in chronic schizophrenia. Schizophrenia Research 2003, 59:137-146.
19. Kaneda Y., Jayathilak K., Meltzer H.Y. Determinants of work outcome in schizophrenia and schizoaffective disorder: role of cognitive function. Psychiatry Research 2009, 169:178-179.
20. Kapogiannis D., Mattson M.P. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurology 2011, 10(2):187-198.
21. Khan M.M., Evans D.R., Gunna V., Scheffer R.E., Parikh V.V., Mahadik S.P. Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-mediated first-episode of psychosis and after years of treatment with antipsychotics. Schizophrenia Research 2002, 58:1-10.
22. Kolosova N.G., Shcheglova T.V., Sergeeva S.V., Loskutova L.V. Long-term antioxidant supplementation attenuates oxidative stress markers and cognitive deficits in senescent-accelerated OXYS rats. Neurobiology of Aging 2006, 27:1289-1297.
23. Lesh T.A., Niendam T.A., Minzenberg M.J., Carter C.S. Cognitive control deficits in schizophrenia: mechanisms and meaning. Neuropsychopharmacology 2011, 36:316-338.
24. Liu Y., Zhu B., Wang X., Luo L., Li P., Paty D.W., et al. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. Journal of Neuroimmunology 2003, 139:27-35.
25. Mesholam-Gately R.I., Giuliano A.J., Goff K.P., Faraone S.V., Seidman L.J. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009, 23(3):315-336.
26. Mukherjee S., Mahadik S.P., Scheefer R., Correnti E.E., Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophrenia Research 1996, 19:19-26.
27. Nagai T., Yamada K., Kim H.C., Kim Y.S., Noda Y., Imura A., et al. Cognition impairment in the genetic model of aging klotho gene mutant mice: a role of oxidative stress. FASEB Journal 2003, 17:50-52.
28. Nicolle M.M., Gonzalez J., Sugaya K., Baskerville K.A., Bryan D., Lund K., et al. Signatures of hippocampal oxidative stress in aged spatial learning-impaired rodents. Neuroscience 2001, 107:415-431.
29. Palmer B.W., Dawes S.E., Heaton R.K. What do we know about neuropsychological aspects of schizophrenia?. Neuropsychology Review 2009, 19:365-384.
30. Radak Z., Kumagai S., Taylor A.W., Naito H., Goto S. Effects of exercise on brain function: role of free radicals. Applied Physiology, Nutrition, and Metabolism 2007, 32(5):942-946.
31. Randolph C., Tierney M.C., Mohr E., Chase T.N. The repeatable battery for the assessment of neuropsychological status (RBANS): preliminary clinical validity. Journal of Clinical and Experimental Neuropsychology 1998, 20:310-319.
32. Ranjekar P.K., Hinge A., Hegde M.V., Ghate M., Kale A., Sitasawad S., et al. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Research 2003, 121:109-122.
33. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophrenia Research 2003, 62:205-212.
34. Sharma T., Antonova L. Cognitive function in schizophrenia. Deficits, functional consequences, and future treatment. Psychiatric Clinics of North America 2003, 26:25-40.
35. Shimoda-Matsubayashi S., Hattori T., Matsumine H., Shinohara A., Yoritaka A., Mori H., et al. Mn SOD activity and protein in a patient with chromosome 6-linked autosomal recessive parkinsonism in comparison with Parkinson's disease and control. Neurology 1997, 49(5):1257-1262.
36. Wisner K.M., Elvevag B., Gold J.M., Weinberger D.R., Dickinson D. Acloser look at siblings of patients with schizophrenia: the association of depression history and sex with cognitive phenotypes. Schizophrenia Research 2011, 126:164-173.
37. Yao J.K., Reddy R., McElhinny L.G., van Kammen D.P. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizophrenia Research 1998, 32:1-8.
38. Yao J.K., Reddy R.D., van Kammen D.P. Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Research 2000, 97:137-151.
39. Yao J.K., Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxidants & Redox Signaling 2011, 15(7):1999-2002.
40. Zhang B.H., Tan Y.L., Zhang W.F., Wang Z.R., Yang G.G., Shi C., et al. Repeatable battery for the assessment of neuropsychological status (RBANS) as a screening test in Chinese: reliability and validity. Chinese Mental Health Journal 2009, 28:865-869.
41. Zhang X.Y., Zhou D.F., Cao L.Y., Zhang P.Y., Wu G.Y. Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Research 2003, 117:85-88.
42. Zhang X.Y., Tan Y.L., Cao L.Y., Wu G.Y., Xu Q., Shen Y., et al. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research 2006, 81(2-3):291-300.
43. Zhang X.Y., Chen da C., Xiu M.H., Yang F.D., Haile C.N., Kosten T.A., et al. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. Journal of Clinical Psychiatry 2012, 73(7):1025-1033.